Regeneron Pharmaceuticals, Inc. REGN
At closeNov 3, 2026, 6:31 PM EST
After hours · Nov 3, 6:31 PM ET
- YTD
- +26.10%
- 1 year
- +51.55%
- Market cap
- 100.69B
- Revenue (ttm)
- 16.90B
- Profit margin
- 28.51%
- EPS (ttm)
- 45.81
- Shares out
- 101.63M
- P/E ratio
- 21.25
- Forward P/E
- 13.79
- Dividend
- 3.76 (0.39%)
- Ex-dividend date
- Nov 19, 2026
- YTD return
- +26.10%
- 1-year return
- +51.55%
- Volume
- 1.20M
- Avg volume
- 746.73K
- Open
- 956.28
- Previous close
- 961.26
- Day's range
- 953.00 – 975.49
- 52-week range
- 591.52 – 975.49
- Beta
- 0.10
- Analysts
- Buy
- Price target
- 976.44 (+0.3%)
- Earnings date
- Jan 28, 2027
5D +166.30 (+20.61%)
Key statistics
- Enterprise value
- 89.87B
- PEG ratio
- 1.64
- Price / sales
- 5.96
- Price / book
- 2.91
- Dividend yield
- 0.39%
- Payout ratio
- 8.18%
- Revenue growth
- 36.30%
- Free cash flow
- 2.58B
- Total cash
- 9.30B
- Total debt
- 2.71B
- Return on equity
- 14.95%
- Short % of float
- 2.18%
- 50-day average
- 795.85
- 200-day average
- 738.63
Analyst view
Consensus: buy
- Target (low)
- 812.00
- Target (mean)
- 976.44
- Target (high)
- 1,175.00
- Strong buy4
- Buy15
- Hold9
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 25.30.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 24.48 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 16.51 | 20.07 | +3.56 | +21.56% |
| Jul 30, 2026 | Jun 30, 2026 | 10.16 | 14.29 | +4.13 | +40.65% |
| Apr 29, 2026 | Mar 31, 2026 | 8.91 | 9.47 | +0.56 | +6.29% |
| Jan 30, 2026 | Dec 31, 2025 | 10.74 | 11.44 | +0.70 | +6.52% |
| Oct 28, 2025 | Sep 30, 2025 | 9.65 | 11.83 | +2.18 | +22.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Nov 2, 2026 | Bernstein | main | Market Perform | Market Perform |
| Nov 2, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 2, 2026 | Truist Securities | main | Buy | Buy |
| Nov 2, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regeneron.com
News
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC's ‘Final Trades' 
UnitedHealth, Cleveland-Cliffs, Regeneron Pharmaceuticals And More: CNBC’s ‘Final Trades’ 
3,572 Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by International Assets Investment Management LLC 
Regeneron Announces Investor Conference Presentations 
Leerink Partners Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $997 
Bernstein Maintains Market Perform on Regeneron Pharmaceuticals, Raises Price Target to $812 
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $855 
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $913 
Truist Securities Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $982 - Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1100
Your note
Sign in to keep a note on REGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN MICHAEL S | Director | Stock Award(Grant) | Jan 1, 2026 | 12,865 |
| FENIMORE CHRISTOPHER R | Chief Financial Officer | Conversion of Exercise of derivative security | Aug 17, 2026 | 23,505 |
| LAROSA JOSEPH J | General Counsel | Conversion of Exercise of derivative security | Aug 18, 2026 | 45,595 |
| MCCOURT MARION E | Officer | Stock Award(Grant) | Dec 4, 2025 | 15,567 |
| MURPHY ANDREW J | Officer | Stock Award(Grant) | Dec 4, 2025 | 56,437 |
| RYAN ARTHUR F. | Director | Sale | Jul 1, 2026 | 17,303 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.97% | 9,113,506 | 8.87B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 6,629,759 | 6.45B | Jun 29, 2026 |
| Dodge & Cox Inc. | 4.79% | 4,871,137 | 4.74B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 4,834,688 | 4.71B | Jun 29, 2026 |
| Invesco Ltd. | 3.88% | 3,940,665 | 3.84B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.71% | 3,774,199 | 3.67B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 3,270,896 | 3.18B | Jun 29, 2026 |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.07% | 3,121,304 | 3.04B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.55% | 2,588,231 | 2.52B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.08% | 2,112,569 | 2.06B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.29% | 1,306,480 | 1.27B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.28% | 1,297,077 | 1.26B | Aug 30, 2026 |